Clinical Trial Update: A Phase 4, Open-label Study of KRYSTEXXA® (Pegloticase) Co-administered With Methotrexate (MTX) in Patients With Uncontrolled Gout (FORWARD OL) [Phase 4]

View source ↗

Summary

Phase 4 open-label trial evaluating co-administration of KRYSTEXXA (pegloticase) with methotrexate in patients with uncontrolled gout; study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gout

Drugs mentioned

• KRYSTEXXA (pegloticase)
• METHOTREXATE (METHOTREXATE)

Snippet

Sponsor: Amgen | Conditions: Uncontrolled Gout, Chronic Gout | Phase 4 | Status: COMPLETED